Yuankai Shi

机构：Oregon Health & Science University, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Laboratory Animal Science · ORCID：0000-0002-3342-4964

发表论文 525 篇 · 总被引 13684 次 · h-index 49

代表论文

• Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000–2025) (2025 · Journal of Hematology & Oncology · 被引 27)
• Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study (2025 · The Lancet Respiratory Medicine · 被引 16)
• Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study (2024 · Journal of Hematology & Oncology · 被引 16)
• A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib (2025 · Signal Transduction and Targeted Therapy · 被引 8)
• First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 8)
• Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma (2024 · Cancer Immunology Immunotherapy · 被引 8)